From Lab to Clinic: CU Anschutz Cancer Center Launches Phase 1 Clinical Trial of Promising Combination Therapy for Resistant Ovarian Cancer
A novel combination of a PARP inhibitor (e.g., Olaparib) with SM08502 (Cirtuvivint) demonstrates promising activity in treating PARP inhibitor–resistant ovarian cancer in a first‑in‑human phase 1 trial.
A phase 1 trial at CU Anschutz is evaluating the safety and preliminary efficacy of combining a PARP inhibitor (Olaparib) with SM08502 (Cirtuvivint) to overcome resistance in high‑grade serous ovarian cancer, targeting both DNA repair and WNT signaling pathways.
PARP inhibitor resistance limits treatment options for many ovarian cancer patients; this combination could expand therapeutic strategies and improve outcomes for a population with few alternatives.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements